Sanofi has signed an agreement to acquire clinical-stage biopharmaceutical company Kymab for an upfront payment of about $1.1bn in cash.
The deal also includes payment of up to $350m on achieving particular milestones.
According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.
Sanofi CEO Paul Hudson said: “The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases.
“The novel mechanism of action may provide treatment for patients with suboptimal responses to available therapies. We look forward to rapidly developing this investigational medicine.”
Last August, Kymab reported that KY1005 met both primary endpoints in a Phase IIa trial that analysed patients with moderate to severe atopic dermatitis.
Kymab’s pipeline also has an ICOS agonist monoclonal antibody, KY1044, which is currently in early Phase I / II development as monotherapy and in combination with an anti-PD-L1.
As well as this oncology asset, Sanofi will have access to Kymab’s latest antibody technologies and research capabilities.
Kymab CEO Simon Sturge said: “The agreement is a testament to the commitment, drive and expertise of the entire Kymab team and we are pleased to receive this endorsement from Sanofi.
“With its significant global resources, we believe Sanofi is the perfect partner to progress Kymab’s pipeline of products and the merger will expedite the time it takes for our novel therapies to get to patients.”
Last November, Sanofi signed a definitive agreement to acquire the entire share capital of Kiadis Pharma in a deal valued at approximately €308m ($359m).
Sanofi anticipates concluding the deal in the first half of this year.
by Pharmaceutical-Technology.com
Source: pharmaceutical-technology.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
